From the Research
The recommended initial imaging modality for acute metastatic melanoma is whole-body PET/CT (positron emission tomography/computed tomography) with FDG (fluorodeoxyglucose). This comprehensive imaging approach allows for simultaneous anatomical and metabolic assessment of the entire body, which is crucial for detecting both obvious and occult metastases. PET/CT is particularly valuable because melanoma cells typically show high glucose metabolism, making them appear as "hot spots" on FDG-PET imaging 1. For patients with known or suspected brain metastases, dedicated brain MRI with contrast should be added to the workup, as it offers superior sensitivity for detecting small brain lesions that may be missed on PET/CT.
The use of PET/CT in metastatic melanoma has been supported by several studies, including one from 2012 that found PET/CT to be useful in detecting unexpected metastases that were missed by conventional imaging 2. Another study from 2011 compared the diagnostic accuracy of FDG-PET/CT and whole-body MRI for detecting bone metastases in patients with non-small cell lung cancer and malignant melanoma, and found that both modalities were equally suitable for this purpose 3.
More recently, a 2022 pilot study used 18F-BMS986192 PET imaging to explore the variability in metastatic tracer uptake and its relation to tumor response in metastatic melanoma patients treated with immune checkpoint inhibitors, with a focus on brain metastases 4. While this study provides new insights into the potential of PET imaging in this context, the primary recommendation for initial imaging modality remains whole-body PET/CT with FDG, given its established role in detecting metastatic disease and guiding treatment planning.
Key points to consider when using PET/CT for acute metastatic melanoma include:
- The importance of simultaneous anatomical and metabolic assessment for detecting both obvious and occult metastases
- The value of dedicated brain MRI with contrast for detecting small brain lesions
- The potential for PET/CT to detect unexpected metastases missed by conventional imaging
- The role of PET/CT in guiding treatment planning and prognosis in melanoma patients.